US 11,939,378 B2
Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target
Lieping Chen, Hamden, CT (US); Scott E. Strome, Rochester, MN (US); and Eugene D. Kwon, Rochester, MN (US)
Assigned to Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed by Mayo Foundation for Medical Education and Research, Rochester, MN (US)
Filed on Aug. 13, 2021, as Appl. No. 17/402,262.
Application 17/402,262 is a continuation of application No. 16/544,357, filed on Aug. 19, 2019, granted, now 11,242,387.
Application 16/544,357 is a continuation of application No. 15/890,048, filed on Feb. 6, 2018, abandoned.
Application 15/890,048 is a continuation of application No. 15/069,258, filed on Mar. 14, 2016, abandoned.
Application 15/069,258 is a continuation of application No. 14/264,568, filed on Apr. 29, 2014, abandoned.
Application 14/264,568 is a continuation of application No. 13/012,063, filed on Jan. 24, 2011, granted, now 8,747,833, issued on Jun. 10, 2014.
Application 13/012,063 is a continuation of application No. 11/245,713, filed on Oct. 6, 2005, granted, now 7,892,540, issued on Feb. 22, 2011.
Claims priority of provisional application 60/642,794, filed on Jan. 11, 2005.
Claims priority of provisional application 60/616,590, filed on Oct. 6, 2004.
Prior Publication US 2021/0380690 A1, Dec. 9, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/00 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 15/113 (2010.01); C12Q 1/6886 (2018.01); G01N 33/50 (2006.01); G01N 33/569 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 38/2013 (2013.01); A61K 38/2026 (2013.01); A61K 38/2066 (2013.01); A61K 38/208 (2013.01); A61K 38/2086 (2013.01); A61K 38/212 (2013.01); A61K 38/215 (2013.01); A61K 38/217 (2013.01); C07K 16/2827 (2013.01); C07K 16/30 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); C12Q 1/6886 (2013.01); G01N 33/5088 (2013.01); G01N 33/5091 (2013.01); G01N 33/56972 (2013.01); G01N 33/57407 (2013.01); G01N 33/57438 (2013.01); G01N 33/57484 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] 3 Claims
 
1. A method for treating renal cell carcinoma in a human comprising administering, to said human, an anti-PD-1 antibody that interferes with an interaction between B7-H1 and PD-1, wherein some or all cells of said renal cell carcinoma express B7-H1.